NCT02224079View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BIIB 722 CL and HPβCD in Young Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 30, 2002

Primary Completion Date

June 30, 2002

Conditions
Healthy
Interventions
DRUG

BIIB 722 CL

DRUG

Placebo

Hydroxypropyl-beta-cyclodextrin (HPβCD)

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY